Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche
Executive Summary
Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid tumultuous leadership transitions, but his tenure was marked by hits and misses.
You may also be interested in...
Sanofi Has The Fire Power For Deals, CEO Hudson Says
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
New Sanofi CEO's Big Priority Is Bolstering R&D
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.
The Challenges Facing Paul Hudson At the Helm of Sanofi
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.